These options are not interchangeable. A pen and IV use NAD+ through different routes and settings, while oral NMN and NR are precursor molecules with their own human evidence. Convenience, supervision and cost can be compared practically, but no format should be called more effective without direct, relevant human comparison evidence.
What exactly is being compared?
| Option | Molecule | Format | Evidence caution |
|---|---|---|---|
| NAD pen | NAD+ | Device-based administration | Direct subcutaneous evidence must be established separately |
| IV NAD+ | NAD+ | Intravenous infusion, normally in a clinical setting | Infusion data do not establish pen outcomes |
| Oral NAD+ | NAD+ | Swallowed formulation | Formulation and study endpoint matter |
| Oral NMN | Nicotinamide mononucleotide | Swallowed NAD precursor | Precursor evidence is not injectable NAD+ evidence |
| Oral NR | Nicotinamide riboside | Swallowed NAD precursor | Product and route differ from NAD+ administration |
Practical differences
A pen routine can involve preparation, storage, needles, disposal and travel. IV involves appointments, travel, infusion time and clinic availability. Oral products have their own label, storage and routine requirements. Total cost can include product, administration, accessories, shipping, consultation and related visits.
Do not assign a universal duration, discomfort level or price to a format. These depend on the actual provider and product. Price does not establish effectiveness.
What the IV evidence shows
A pilot study of 11 healthy male participants examined plasma and urine metabolites during and after a six-hour intravenous NAD+ infusion, with eight receiving NAD+ and three receiving saline.[1] It provided early pharmacokinetic information, not evidence of anti-ageing, energy, cognition or other wellness benefits. It does not show that IV NAD+ is superior to a pen or oral precursor.
What NMN and NR studies show
Oral NR increased NAD+ in peripheral blood mononuclear cells in a small randomized crossover trial of healthy middle-aged and older adults. Several physiological outcomes were exploratory.[2] A 60-day randomized trial of oral NMN in 80 healthy middle-aged adults reported increased blood NAD concentrations and changes in some secondary measures.[3]
These results do not establish the effects of injected NAD+ or justify transferring a studied regimen to another product.
Is a pen better absorbed?
This guide does not make that claim. A route-based bioavailability statement requires relevant pharmacokinetic evidence for the specific molecule and formulation. IV delivery cannot quantify subcutaneous absorption, and oral precursor data cannot supply the missing comparison.
How to choose a context, not a winner
- Confirm the goal with a qualified professional.
- Check direct evidence for the same molecule, route and population.
- Review safety and supervision.
- Inspect product quality documents.
- Assess the real routine and total cost.
The bottom line
Different formats answer different practical needs, but the selected studies are not head-to-head efficacy trials. No effect size can be ranked across them. Continue with our NAD pen checklist or review the NAD.Power product facts.
Sources: [1] Grant et al., 2019 · [2] Martens et al., 2018 · [3] Yi et al., 2023. Direct human evidence for oral NAD+ and subcutaneous NAD+ requires separate formulation- and route-specific review.